沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响  

Effect of Sacubitril/Valsartan on Clinical Symptoms and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction

作　　者：邱隆霞 QIU Longxia(Department of Pharmacy,Shangrao Guangfeng District People's Hospital,Shangrao 334600,Jiangxi,China)

机构地区：[1]上饶市广丰区人民医院药剂科,江西上饶334600

出　　处：《医学信息》2025年第9期92-96,共5页Journal of Medical Information

摘　　要：目的探究沙库巴曲缬沙坦对射血分数保留心功能衰竭患者临床症状及心功能的影响。方法选取2021年1月-2023年6月上饶市广丰区人民医院收治的射血分数保留心功能衰竭患者62例为研究对象,根据随机数字表法分为对照组与研究组,各31例。对照组采取常规治疗,研究组采取沙库巴曲缬沙坦口服治疗。比较两组临床疗效、心功能[左心室舒张末期内径(LVDd)、左心室收缩末期内径(LVDs)、室间隔舒张末期厚度(IVSd)、左心室后壁舒张末期厚度(LVPWd)]、心血管不良事件(心血管死亡、恶性心律失常、心力衰竭加重)发生率、炎性因子水平[超敏C反应蛋白(hs-CRP)、白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α]、临床症状(呼吸困难、体力活动受限、胸闷、气短)评分。结果与对照组治疗总有效率的74.19%比较,研究组治疗总有效率更高,达96.77%(P<0.05);与对照组心血管不良事件发生率的16.13%比较,研究组心血管不良事件发生率更低,为0(P<0.05);与治疗前比较,两组治疗后心功能指标(LVDd、LVDs、IVSd、LVPWd)、炎性因子水平(hs-CRP、IL-6、TNF-α)、临床症状评分(呼吸困难、体力活动受限、胸闷、气短)降低,且与对照组比较,研究组治疗后心功能指标(LVDd、LVDs、IVSd、LVPWd)、心功能指标(LVDd、LVDs、IVSd、LVPWd)、炎性因子水平(hs-CRP、IL-6、TNF-α)、临床症状评分(呼吸困难、体力活动受限、胸闷、气短)更低(P<0.05)。结论沙库巴曲缬沙坦在射血分数保留心功能衰竭患者治疗中的临床疗效确切,能够改善患者心功能及临床症状,减轻患者炎性反应,降低患者心血管不良事件发生率。Objective To investigate the effect of sacubitril/valsartan on clinical symptoms and cardiac function in patients with heart failure with preserved ejection fraction.Methods A total of 62 patients with heart failure with preserved ejection fraction admitted to Shangrao Guangfeng District People's Hospital from January 2021 to June 2023 were selected as the research objects.According to the random number table method,they were divided into control group and study group,with 31 patients in each group.The control group was treated with routine treatment,and the study group was treated with sacubitril/valsartan orally.The clinical efficacy,cardiac function[left ventricular end-diastolic diameter(LVDd),left ventricular end-systolic diameter(LVDs),interventricular septal thickness in diastole(IVSd),left ventricular posterior wall end-diastolic thickness(LVPWd)],incidence of cardiovascular adverse events(cardiovascular death,malignant arrhythmia,aggravation of heart failure),levels of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin(IL)-6,tumor necrosis factor(TNF)-α],clinical symptoms(dyspnea,physical activity limitation,chest tightness,shortness of breath)scores were compared between the two groups.Results Compared with 74.19%of the total effective rate of the control group,the total effective rate of the study group was higher,reaching 96.77%(P<0.05).Compared with 16.13%of the incidence of cardiovascular adverse events in the control group,the incidence of cardiovascular adverse events in the study group was lower,which was 0(P<0.05).Compared with before treatment,the cardiac function indexes(LVDd,LVDs,IVSd,LVPWd),inflammatory factor levels(hs-CRP,IL-6,TNF-α)and clinical symptom scores(dyspnea,physical activity limitation,chest tightness,shortness of breath)decreased in the two groups after treatment,and compared with the control group,the cardiac function indexes(LVDd,LVDs,IVSd,LVPWd),cardiac function indexes(LVDd,LVDs,IVSd,LVPWd),inflammatory factor levels(hs-CRP,IL-6,TNF-α),clinical

关 键 词：沙库巴曲缬沙坦 射血分数保留心功能衰竭 心功能 

分 类 号：R541.61[医药卫生—心血管疾病]